ArticleJournal of materials science. Materials in medicine2025
Construction of aptamer functionalized camptothecin incorporated chitosan-palladium/gold nanoparticles delivery improved photothermal activity and anti-lung carcinoma cells.
Article in Journal of materials science. Materials in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to develop a versatile aptamer-conjugated, photothermal responsive camptothecin (CPT)-loaded chitosan-bimetallic (Pd/Au) nanoparticles (Ap-CH-CPT-Pd/Au NPs) to enhance cytotoxicity in lung cancerous NCI-H446 and H1299 cells. The CH-CPT-Pd/Au NPs exhibited polydispersity with a diameter of 33.87 ± 2.23 nm. FTIR investigation revealed the presence of chitosan and camptothecin in chitosan-camptothecin-palladium/gold nanoparticles. The 2θ of CH-CPT-Pd/Au corresponded to chitosan and palladium/gold. The Ap-CH-CPT-Pd/Au NPs (180 μg/mL) subjected to near-infrared (NIR) treatment elevated the temperature to over 50 °C. The optimum CPT concentration was 0.075% in CH-CPT-Pd/Au, demonstrating a hydrodynamic diameter of 113.12 ± 16.78 nm, a drug loading efficiency (DLE) of 10.89 ± 0.53%, and a drug encapsulation efficiency (DEE) of 63.97 ± 4.21%. A CPT release rate of 7.23 ± 3.25% was recorded at pH = 5.4 after 74 h. In addition, NIR+Ap-CH-CPT-Pd/Au NPs exhibited negligible toxicity to red blood cells (RBCs). However, enhanced cytotoxicity in NCI-H446 and H1299 lung carcinoma cells is achieved through the induction of oxidative stress-mediated apoptosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.